Charles River Laboratories International (CRL) Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRL shares.
View CRL analyst ratings or view top-rated stocks.

10 Wall Street research analysts have issued 12 month price targets for Charles River Laboratories International's shares. Their CRL share price forecasts range from $203.00 to $315.00. On average, they expect the company's stock price to reach $260.73 in the next twelve months. This suggests a possible upside of 28.7% from the stock's current price.
View analysts price targets for CRL or view top-rated stocks among Wall Street analysts.

Charles River Laboratories International's stock was trading at $217.90 at the start of the year. Since then, CRL shares have decreased by 7.0% and is now trading at $202.56.
View the best growth stocks for 2023 here.

Charles River Laboratories International saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 1,340,000 shares, a drop of 13.0% from the April 30th total of 1,540,000 shares. Based on an average daily volume of 607,300 shares, the short-interest ratio is currently 2.2 days. Currently, 2.7% of the shares of the stock are short sold.
View Charles River Laboratories International's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our CRL earnings forecast.

Charles River Laboratories International, Inc. (NYSE:CRL) announced its quarterly earnings data on Wednesday, February, 22nd. The medical research company reported $2.98 earnings per share for the quarter, beating analysts' consensus estimates of $2.75 by $0.23. The medical research company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.04 billion. Charles River Laboratories International had a trailing twelve-month return on equity of 20.12% and a net margin of 12.13%. The business's revenue was up 21.5% on a year-over-year basis. During the same quarter last year, the business posted $2.49 EPS.
Read the conference call transcript.

ETFs with the largest weight of Charles River Laboratories International (NYSE:CRL) stock in their portfolio include Future Fund Active ETF (FFND), First Trust NYSE Arca Biotechnology Index Fund (FBT), Simplify Health Care ETF (PINK), Horizon Kinetics Inflation Beneficiaries ETF (INFL), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX), AdvisorShares Dorsey Wright Alpha Equal Weight ETF (DWEQ) and BlackRock Future Innovators ETF (BFTR).

Charles River Laboratories International issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of $9.90-$10.90 for the period, compared to the consensus EPS estimate of $10.24. The company issued revenue guidance of $4.06 billion-$4.16 billion, compared to the consensus revenue estimate of $4.09 billion.

291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM), Abbott Laboratories (ABT), Mastercard (MA), Intuitive Surgical (ISRG) and Johnson & Johnson (JNJ).

Charles River Laboratories International trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRL."

Charles River Laboratories International's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.35%), Price T Rowe Associates Inc. MD (4.90%), State Street Corp (4.01%), Kayne Anderson Rudnick Investment Management LLC (3.18%), Clearbridge Investments LLC (2.75%) and Allspring Global Investments Holdings LLC (2.26%). Insiders that own company stock include Birgit Girshick, David Ross Smith, Deborah Turner Kochevar, George Massaro, James C Foster, James C Foster, Joseph W Laplume, Michael Gunnar Knell, Richard F Wallman, Shannon M Parisotto, Stephen D Chubb, Victoria L Creamer, William D Barbo and William D Barbo.
View institutional ownership trends.

Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRL stock can currently be purchased for approximately $202.56.

Charles River Laboratories International (NYSE:CRL) has a market capitalization of $10.37 billion and generates $3.98 billion in revenue each year. The medical research company earns $486.23 million in net income (profit) each year or $9.67 on an earnings per share basis.

The company employs 21,400 workers across the globe.

Charles River Laboratories International's mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The official website for the company is www.criver.com. The medical research company can be reached via phone at (781) 222-6000, via email at askcharlesriver@crl.com, or via fax at 978-988-5665.